149 related articles for article (PubMed ID: 37068034)
1. Escaping the Long Shadow Cast by Agranulocytosis: Reflections on Clozapine Pharmacovigilance Focused on the United Kingdom.
de Leon J; Arrojo-Romero M; Verdoux H; Ruan CJ; Schoretsanitis G; Rohde C; Cohen D; Schulte PFJ; Kim SH; Cotes RO; Leung JG; Otsuka Y; Kirilochev OO; Baptista T; Grover S; Every-Palmer S; Clark SR; McGrane IR; Motuca M; Olmos I; Wilkowska A; Sagud M; Anil Yağcioğlu AE; Ristic DI; Lazary J; Sanz EJ; De Las Cuevas C
J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):239-245. PubMed ID: 37068034
[TBL] [Abstract][Full Text] [Related]
2. Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: Comparing the top four reporting countries (US, UK, Canada and Australia).
De Las Cuevas C; Sanz EJ; de Leon J
Schizophr Res; 2024 Jun; 268():165-174. PubMed ID: 37301669
[TBL] [Abstract][Full Text] [Related]
3. Revealing the reporting disparity: VigiBase highlights underreporting of clozapine in other Western European countries compared to the UK.
De Las Cuevas C; Sanz EJ; Gross JA; Correll CU; Verdoux H; Lally J; de Filippis R; Schulte PFJ; Molden E; Arrojo-Romero M; Bostrom AD; Schoretsanitis G; Fernandez-Egea E; de Leon J
Schizophr Res; 2024 Jun; 268():175-188. PubMed ID: 38065799
[TBL] [Abstract][Full Text] [Related]
4. An expert review of clozapine in Latin American countries: Use, monitoring, and pharmacovigilance.
Baptista T; Motuca M; Serrano A; Perez Lo Presti A; Fernandez-Arana A; Olmos I; Pabon A; Yepez JGA; Alejo Galarza GJ; Rivera Ramirez NM; Elkis H; Sanz EJ; De Las Cuevas C; de Leon J
Schizophr Res; 2024 Jun; 268():60-65. PubMed ID: 37985318
[TBL] [Abstract][Full Text] [Related]
5. An expert review of clozapine in Eastern European countries: Use, regulations and pharmacovigilance.
Sagud M; Breznoscakova D; Celofiga A; Chihai J; Chkonia E; Ristic Ignjatovic D; Injac Stevovic L; Kopecek M; Kurvits K; Kuzo N; Lazáry J; Mazaliauskienė R; Mladina Perisa D; Novotni A; Panov G; Pikirenia U; Rădulescu FȘ; Sukiasyan SG; Taube M; Tomori S; Wilkowska A; De Las Cuevas C; Sanz EJ; de Leon J
Schizophr Res; 2024 Jun; 268():53-59. PubMed ID: 37783650
[TBL] [Abstract][Full Text] [Related]
6. Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland.
Atkin K; Kendall F; Gould D; Freeman H; Liberman J; O'Sullivan D
Br J Psychiatry; 1996 Oct; 169(4):483-8. PubMed ID: 8894200
[TBL] [Abstract][Full Text] [Related]
7. Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.
Munro J; O'Sullivan D; Andrews C; Arana A; Mortimer A; Kerwin R
Br J Psychiatry; 1999 Dec; 175():576-80. PubMed ID: 10789357
[TBL] [Abstract][Full Text] [Related]
8. Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries.
De Las Cuevas C; Sanz EJ; Ruan CJ; de Leon J
Rev Psiquiatr Salud Ment (Engl Ed); 2022; 15(4):238-250. PubMed ID: 36513400
[TBL] [Abstract][Full Text] [Related]
9. [Intensive pharmacovigilance of clozapine in Argentina].
Balda MV; Daray FM
Vertex; 2015; 26(122):292-301. PubMed ID: 26672506
[TBL] [Abstract][Full Text] [Related]
10. According to the WHO clozapine pharmacovigilance database, the United Kingdom accounts for 968 fatal outcomes versus 892 in the rest of the world.
de Leon J
Br J Clin Pharmacol; 2022 Dec; 88(12):5434-5435. PubMed ID: 36106607
[No Abstract] [Full Text] [Related]
11. Data From the World Health Organization's Pharmacovigilance Database Supports the Prominent Role of Pneumonia in Mortality Associated With Clozapine Adverse Drug Reactions.
De Leon J; Sanz EJ; De Las Cuevas C
Schizophr Bull; 2020 Jan; 46(1):1-3. PubMed ID: 31901099
[No Abstract] [Full Text] [Related]
12. The safety of clozapine in the elderly.
Gareri P; De Fazio P; Russo E; Marigliano N; De Fazio S; De Sarro G
Expert Opin Drug Saf; 2008 Sep; 7(5):525-38. PubMed ID: 18759705
[TBL] [Abstract][Full Text] [Related]
13. Clozapine-Induced Gastrointestinal Hypomotility: A 22-Year Bi-National Pharmacovigilance Study of Serious or Fatal 'Slow Gut' Reactions, and Comparison with International Drug Safety Advice.
Every-Palmer S; Ellis PM
CNS Drugs; 2017 Aug; 31(8):699-709. PubMed ID: 28623627
[TBL] [Abstract][Full Text] [Related]
14. Reporting of clozapine-induced gastrointestinal hypomotility and factors associated with fatal outcomes in Canada: A pharmacovigilance database study.
Liu CL; Maruf AA; Bousman CA
Psychiatry Res; 2020 Aug; 290():113048. PubMed ID: 32474068
[TBL] [Abstract][Full Text] [Related]
15. Clozapine-associated neutropenia and agranulocytosis in Argentina (2007-2012).
Balda MV; Garay OU; Papale RM; Bignone I; Bologna VG; Brandolini A; Prokopez CR; Balasini JI; Baldessarini RJ; Daray FM
Int Clin Psychopharmacol; 2015 Mar; 30(2):109-14. PubMed ID: 25486383
[TBL] [Abstract][Full Text] [Related]
16. Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted.
Lahdelma L; Appelberg B
J Clin Psychiatry; 2012 Jun; 73(6):837-42. PubMed ID: 22480452
[TBL] [Abstract][Full Text] [Related]
17. Haematologic malignancies associated with clozapine
Chrétien B; Lelong-Boulouard V; Chantepie S; Sassier M; Bertho M; Brazo P; Humbert X; Alexandre J; Fedrizzi S; Dolladille C
Psychol Med; 2021 Jul; 51(9):1459-1466. PubMed ID: 32036793
[TBL] [Abstract][Full Text] [Related]
18. Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry.
Honigfeld G; Arellano F; Sethi J; Bianchini A; Schein J
J Clin Psychiatry; 1998; 59 Suppl 3():3-7. PubMed ID: 9541331
[TBL] [Abstract][Full Text] [Related]
19. [Hematologic effects of clozapine: a review of the international experience].
Lamarque V
Encephale; 1996 Dec; 22 Spec No 6():35-6. PubMed ID: 9102319
[TBL] [Abstract][Full Text] [Related]
20. Effects of the clozapine national registry system on incidence of deaths related to agranulocytosis.
Honigfeld G
Psychiatr Serv; 1996 Jan; 47(1):52-6. PubMed ID: 8925346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
